Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
NCT00104377 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70
Last updated 2010-06-17
Summary
Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assessed.
Conditions
- Type I Hypersensitivity
Interventions
- BIOLOGICAL
-
Grass MATA MPL
Sponsors & Collaborators
-
Allergy Therapeutics
lead INDUSTRY
Principal Investigators
-
Paul H. Ratner, MD · Sylvana Research Associates
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-03-31
- Completion
- 2005-11-30
Countries
- United States
Study Locations
More Related Trials
-
Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
NCT00113750 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety/Tolerability of Ragweed MATA MPL
NCT00423787 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of the Contribution of Monophosphoryl Lipid A (MPL) to a Grass Pollen Allergy Vaccine
NCT00133146 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Efficacy and Safety of Ragweed MATAMPL, Pollinex-R and Placebo in Patients With Ragweed Allergy
NCT00110786 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Safety+Efficacy of Different Doses of RagweedMATAMPL;Assessment of Residual Allergenicity Using Skin Prick Test
NCT00258635 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis
NCT00309036 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)
NCT00109759 ·Status: WITHDRAWN ·Phase: PHASE1
-
Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy
NCT02676765 ·Status: TERMINATED ·Phase: PHASE3
-
Long-term Efficacy and Safety Study With Oralgen Grass Pollen
NCT00824447 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
NCT00841256 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Specific Immunotherapy With CLUSTOID Grass Pollen
NCT01012531 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of ToleroMune Ragweed to Treat Ragweed Allergy in Ragweed Allergic Subjects With Rhinoconjunctivitis
NCT00878774 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Immunological Effect and Efficacy of the Combined Application of MPL and Grass Pollen Allergen
NCT00241410 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerance Study of Grass Pollen-derived Peptides to Treat Allergic Rhinitis
NCT00813046 ·Status: COMPLETED ·Phase: PHASE1
-
Follow-up Investigation of Efficacy of Ragweed MATAMPL,and Placebo in Patients With Ragweed-induced Seasonal Allergic Rhinitis
NCT00325338 ·Status: COMPLETED ·Phase: PHASE2
-
Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
NCT05297760 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis
NCT00833066 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis
NCT00955825 ·Status: COMPLETED ·Phase: PHASE3
-
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
NCT06104293 ·Status: COMPLETED ·Phase: NA
-
Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat Rhinoconjunctivitis
NCT00550875 ·Status: COMPLETED ·Phase: PHASE2
-
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy
NCT05191186 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
NCT00264459 ·Status: COMPLETED ·Phase: PHASE3
-
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
NCT04502966 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety From a High-dosed Sublingual Grass Pollen Preparation
NCT00623701 ·Status: COMPLETED ·Phase: PHASE3
-
A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis
NCT00812799 ·Status: UNKNOWN ·Phase: PHASE3